DEVELOPMENT OF PROTEINS FOR KITS OF RUBELLA DIAGNOSIS AIMING TO TRANSFER TECHNOLOGY
Rubella virus; German measles; Rubella diagnosis
Rubella is a disease of epidemiological importance caused by infection with the rubella virus (RV). The virus is transmitted by infected people through airborne droplets. Many cases of congenital anomalies or fetal deaths have been reported after survived by RV during the first 16 weeks of pregnancy. These congenital anomalies are particular to Down syndrome. congenital rubella (CRS). In addition, after birth, the child with CRS may present with deafness, eye disorders and heart diseases, in addition to other late sequelae, including autism, diabetes mellitus and thyroid dysfunction. One of the biggest challenges for the control of Rubella consist in the development of diagnostic strategies that ensured its identification with high accuracy, and, at the same time, can be applied in poor or developing countries. This means that the method the diagnosis necessarily needs to present high performance, reproducibility, in addition to having a low production cost. These premises are fundamental in the incorporation of the diagnostic tool for application to the Unified Health System (SUS), or still intended for private clinical analysis laboratories, resulted in greater diagnostic efficiency and cost reduction. Our group has been working with the strategy of producing innovative proteins, expressed in Escherichia coli (E. coli), which resulted in more sensitive tests with lower production costs. Among the recombinant proteins developed by us group is the recombinant multiepitope chimera called rMERUB, developed by SOUZA et al. (2021), which in preliminary ELISA assays, results proved promising for diagnosing rubella. The present work has with the objective of improving the preliminary results obtained by the authors, in addition to developing new technologies for the production of antigens applied as inputs in the diagnosis by ELISA for Rubella.